Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?

被引：29
|
作者：
Funamizu, Naotake [1 ,2 ]
Okamoto, Aikou [4 ]
Kamata, Yuko [3 ]
Misawa, Takeyuki [1 ]
Uwagawa, Tadashi [1 ]
Gocho, Takeshi [1 ]
Yanaga, Katsuhiko [1 ]
Manome, Yoshinobu [2 ]
机构：
[1] Jikei Univ, Sch Med, Dept Surg, Minato Ku, Tokyo 1058461, Japan
[2] Jikei Univ, Sch Med, Dept Mol Cell Biol, Minato Ku, Tokyo 1058461, Japan
[3] Jikei Univ, Sch Med, Inst DNA Med, Minato Ku, Tokyo 1058461, Japan
[4] Jikei Univ, Sch Med, Dept Gynecol, Minato Ku, Tokyo 1058461, Japan
来源：
ONCOLOGY REPORTS | 2010年 / 23卷 / 02期
关键词：
gemcitabine; pancreatic cancer; deoxycytidine kinase; deoxycytidine deaminase; tetra-hydro uridine; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER-1; CELL LUNG-CANCER; IN-VIVO; CYTOSINE-ARABINOSIDE; INCREASED EXPRESSION; CYTIDINE DEAMINASE; ANTITUMOR-ACTIVITY; GENE-THERAPY; ADENOCARCINOMA; SENSITIVITY;
D O I：
10.3892/or_00000657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of pancreatic cancer remains poor, and the standard first-line chemotherapy with gemcitabine (GEM) has a response rate of less than 20%. Since expression of deoxycytidine kinase (dCK) seems important for improvement of GEM sensitivity, overexpression of dCK was investigated using pancreatic cancer cell lines (Panc-1, MIAPaCa-2 and BxPC-3). dCK gene was introduced into the cell lines by retrovirus and changes in IC50 were examined. Sensitivity of two pancreatic cancer cell lines to GEM elevated dramatically in comparison with control cells, but change of sensitivity remained at 1.8 times in BxPC-3. Since addition of tetrahydro uridine (THU), an inhibitor of deoxycytidine deaminase (CDA), increased the sensitivity 54-fold, overexpression of CDA seems to be the mechanism for improvement of the sensitivity. In Conclusion, dCK is a key enzyme of GEM, but resistance of GEM is not improved in all pancreatic cancer cells by overexpression of dCK. Combination treatment based on expression of GEM metabolism-related gene may become an effective therapy in the future.
引用
收藏
页码：471 / 475
页数：5
相关论文
共 50 条
  • [1] Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer
    Ohhashi, Seir
    Ohuchida, Kenki
    Mizumoto, Kazuhiro
    Fujita, Hayato
    Egami, Takuya
    Yu, Jun
    Toma, Hiroki
    Sadatomi, Shoko
    Nagai, Eishi
    Tanaka, Masao
    ANTICANCER RESEARCH, 2008, 28 (4B) : 2205 - 2212
  • [2] Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer
    Dash, Suman
    Ueda, Takeshi
    Komuro, Akiyoshi
    Honda, Masahiko
    Sugisawa, Ryoichi
    Okada, Hitoshi
    CELL DEATH & DISEASE, 2024, 15 (02)
  • [3] Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival
    Sebastiani, V
    Ricci, F
    Rubio-Viquiera, B
    Kulesza, P
    Yeo, CJ
    Hidalgo, M
    Klein, A
    Laheru, D
    Iacobuzio-Donahue, CA
    CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2492 - 2497
  • [4] Immunohistochemical labeling for deoxycytidine kinase (dCK) in pancreatic cancer correlates with response to gemcitabine
    Sebastiani, V
    Witzel, S
    Ricci, F
    Laheru, D
    Iacobuzio-Donahue, C
    MODERN PATHOLOGY, 2005, 18 : 286A - 286A
  • [5] Immunohistochemical labeling for deoxycytidine kinase (dCK) in pancreatic cancer correlates with response to gemcitabine
    Sebastiani, V
    Witzel, S
    Ricci, F
    Laheru, D
    Iacobuzio-Donahue, C
    LABORATORY INVESTIGATION, 2005, 85 : 286A - 286A
  • [6] MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
    Dash, Suman
    Ueda, Takeshi
    Komuro, Akiyoshi
    Amano, Hisayuki
    Honda, Masahiko
    Kawazu, Masahito
    Okada, Hitoshi
    MOLECULAR CANCER RESEARCH, 2023, 21 (05) : 444 - 457
  • [7] Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer (vol 15, 131, 2024)
    Dash, Suman
    Ueda, Takeshi
    Komuro, Akiyoshi
    Honda, Masahiko
    Sugisawa, Ryoichi
    Okada, Hitoshi
    CELL DEATH & DISEASE, 2024, 15 (05):
  • [8] Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase
    Vena, Francesca
    Bayle, Simon
    Nieto, Ainhoa
    Quereda, Victor
    Aceti, Massimiliano
    Frydman, Sylvia M.
    Sansil, Samer S.
    Grant, Wayne
    Monastyrskyi, Andrii
    McDonald, Patricia
    Roush, William R.
    Teng, Mingxiang
    Duckett, Derek
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (08) : 1623 - 1635
  • [9] The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
    Costantino, Christina L.
    Witkiewicz, Agnieszka K.
    Kuwano, Yuki
    Cozzitorto, Joseph A.
    Kennedy, Eugene P.
    Dasgupta, Abhijit
    Keen, Judith C.
    Yeo, Charles J.
    Gorospe, Myriam
    Brody, Jonathan R.
    CANCER RESEARCH, 2009, 69 (11) : 4567 - 4572
  • [10] Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance
    Dalin, Simona
    Sullivan, Mark R.
    Lau, Allison N.
    Grauman-Boss, Beatrice
    Mueller, Helen S.
    Kreidl, Emanuel
    Fenoglio, Silvia
    Luengo, Alba
    Lees, Jacqueline A.
    Vander Heiden, Matthew G.
    Lauffenburger, Douglas A.
    Hemann, Michael T.
    CANCER RESEARCH, 2019, 79 (22) : 5723 - 5733
12345